P/B
1,8
Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
$351.6M
Market Cap • 11/13/2026
2018
(8 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
23438,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,8
EPS
—
Market Cap
Market Cap
351,6M
EV
208,8M
EV/Revenue
13918,8
EV/EBITDA
-0,8
EV/EBIT
-0,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-14,9%
Total Yield
-14,9%
Payout
0%
Retained Earnings
-1,7B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
1128170%
Capex/Revenue
4766,7%
Capex/D&A
7,9%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
16,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-72,8%
CAGR Op. Income 5Y
5,3%
CAGR Net Income 5Y
4,4%
CAGR EPS 5Y
-38,5%
CAGR OCF 5Y
3,1%
Leverage
N.D./EBITDA
0,6
Debt/Equity
0%
Current Ratio
4
Quick Ratio
3,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!